Losartan versus enalapril in dogs asymptomatic carriers of myxomatous degeneration of mitral valve

Losartan versus enalapril in dogs asymptomatic carriers of myxomatous degeneration of mitral valve

Contenido principal del artículo



The myxomatous mitral valve degeneration (DMVM) is the most common heart disease in dogs. The treatment of congestive heart failure (CHF) from DMVM is based on the use of angiotensin-converting enzyme inhibitors (ACE inhibitor) Receptor antagonists of angiotensin II (ARBs) promote complete blockade of angiotensin II, and are used in the treatment of CHF in humans, but is not common in dogs. The objective of this research was to compare the clinical responses of dogs carriers DMVM treated with enalapril-ACE inhibitors, losartan-ARBs. Thirteen dogs with DMVM and ICC class Ib were randomized into two groups as follows: G1-enalapril and G2-losartan. On physical examination, electrocardiogram and blood pressure were measured on days 0, 14, 28 and 56 after the begging of treatment. Radiographic measure, Vertebral Heart Size-VHS and ecodopplercardiográficas variables were obtained on days 0 and 56. Data were subjected to analysis of variance with repeated measures. There was no difference (P>0.05) for ecodopplercardiográficas, electrocardiographic and radiographic variables between the groups studied. In relation to time, there was a decrease (P <0.05) of the VHS, duration of the P wave and the QRS complex variables. We conclude that losartan acts similarly to enalapril in the initial treatment (first 56 days) of dogs with DMVM class Ib and II of the CHF.

Palabras clave:


Los datos de descargas todavía no están disponibles.

Detalles del artículo

Referencias (VER)

ABBOT, J. A. 2000. Chapter 34: Degenerative valvular disease. Págs. 212-213 en Aboott, J.A. (Ed.) Small Animal Cardiology Secrets. Hanley & Belfus, Inc, Philadelphia.

ATKINS, C.E., BROWN, A.W., COATS, J.R. et al. 2002. Efects of long-term administration of enalapril on clinical indicatons of renal function in dogs with compensated mitral regurgitation. Journal of the American Veterinary Medical Association 21: 654-658.

ATKINS, C.E., HAGGSTROM, J. 2012. Pharmacologic management of myxomatous mitral valve disease in dogs. Journal of Veterinary Cardiology 14: 165-184.

BOON, J.A. 2011. Acquired heart disease. Cap 5, Págs 267-334 en: Boon JA, Manual of Veterinary Echocardiography. Baltinore: Willians y Wilkins, USA.

BORGARELLI, M., HAGGSTROM, J. 2010. Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy. Veterinary Clinics of North America: Small Animal Practice 40: 651-663.

BORGARELLI, M., BUCHANAN, J.W. 2012. Historical review, epidemiology and natural history of degenerative mitral valve disease. Journal of Veterinary Cardiology 14: 93 -101.

BUCHAMAN, J.W., BUCHELER, J. 1995. Vertebral scale system to measure canine Heart size in radiographs. Journal of Veterinary Internal Medicine 206: 194-199.

BUCHAMAN, J.W. 1997. Chronic valvular disease (endocardiose) in dogs. Advances in Veterinary Science 21: 75-106.

CALVERT, C.A. 1991. Efect of medical therapy on survival of patients with dilated cardiomyopathy. Veterinary Clinics of North America: Small Animal Practice 21: 919-930.

CHIU, A.T., HERBLIN, W.F., MCCALL, D.E., PRICE, W.A., WONG, P.C., CARINI, D.J. et al. 1990. Angiotensin II receptor subtypes and their selective nonpeptide ligands. Receptor 1: 33-40.

COBB, M.A. 2000. Capítulo 12: Insuficiencia cardíaca izquierda. Págs 225-44 en Luis Fuentes, V. y SWIFT, S.T. Manual de Medicina y Cirugía Cardiorrespiratoria. Editorial Harcourt. España.

CROZIER, I., IKRAM, H., AWAN, N. et al. 1995 Losartana in heart failure: hemodynamic effects and tolerability. Circulation 91, 691-697.

DE MORAIS, H.A. 2000. Pathophysiology of heart failure and evaluation of cardiac function. Págs 692-712 en: Ettinger SJ, Feldman EC. Textbook of Veterinary Internal Medicine. 5º edición. Editorial Saunders. Philadelphia.

DICKSTEIN, K., CHANG, P., WILLENHEIMER, R., HAUNSØ, S., REMES, J., HALL, C., KJEKSHUS, J. 1995. Comparison of the efectts of losartan and enalapril on clinical status and exercise performance in with moderate or severe chronic heart failure patients. Journal of the American College of Cardiology 26, Issue 2: 438–445.

FRANCO, R.P. 2009. Avaliação clínica da utilização da furosemida, maleato de enalapril, espironolactona e suas combinações em cães com endocardiose de válvula mitral. Dissertação de mestrado – Faculdade de ciências Agrárias e Veterinárias, Universidade Estadual Paulista, Jaboticabal.

FRANCO, R.P., CHAMPION, T., PASCON, J.P.E., NETO, G.B.P., JUNIOR, D.P., CAMACHO, A.A. 2011. Utilização do maleato de enalapril, furosemida, espironolactona e suas associações em cães com doença degenerativa mixomatosa da válvula mitral. ARS Veterinária 2: 85-93.

HÄGGSTRÖM, J., HANSSON, K., KVART, C., KARLBERG, B.E., VUOLTEENAHO, O., OLSSON, K. 1997. Effects of naturally acquired decompensated mitral valve regurgitation on the rennin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs. American Journal of Veterinary Research, 58: 77-82.

HAMLIN, R.L., BENITZ, A.M., ERICSSON, G.F., CIFELLI, S., DAURIO, C.P. 1996. Effects of enalapril on exercise tolerance and longevity in dogs with heart failure produced by iatrogenic mitral regurgitation. Journal of Veterinary Internal Medicine 2: 85-87.

International Small Animal Cardiac Health Council (ISACHC). 1995. Recommendations for the diagnosis of heart disease and the treatment of heart failure in small animals. In: Miller MS, Tilley LP, eds. Manual of canine and feline cardiology. 2nd ed. Philadelphia: WB Saunders.

KIENLE, R.D., THOMAS, W.P. 1995. Echocardiography. Págs.198-255 en: Nyland TG, Mattoon JS. Veterinary Diagnostic Ultrasound. 2ª ed. Editorial Saunders. Philadelphia.

KITAGAWA, H., WAKAMIYA, H., KITOH, K. et al. 1997. Efficacy of monotherapy with benazepril, an angiotensin-converting enzyme inhibitor, in dogs with naturally acquired chronic mitral insufficiency. Journal of Veterinary Medical Science 59: 513-520.

KITTLESON, M.D. 2006. Myxomatous atrioventricular valvular degeneration. Págs. 52 en: Kittleson MD. Textbook of Cardiovascular Medicine, 3º ed. en DVD, St Louis: Mosby DVD.

MUCHA, C.J., CAMACHO, A.A. 2007. Afecciones Cardiovasculares en Pequeños Animales. Págs. 179-183. Segunda edición. Editorial Inter.-Medica, Buenos Aires.

PARKER, H.G., KILROY-GLYNN, P. 2012. Myxomatous mitral valve disease in dogs: Does size matter?. Journal of Veterinary Cardiology 14: 19- 29.

PEREIRA, J.D.G. 1996. Variações de parâmetros clínicos-laboratoriais de cães tratados com furosemida. Dissertação de mestrado – Faculdade de ciências Agrárias e Veterinárias, Universidade Estadual Paulista, Jaboticabal.

PEREIRA, P.M., CAMACHO, A.A., MORAIS, H.A. 2005. Tratamento da insuficiência cardíaca com benazepril em cães com cardiomiopatia dilatada e endocardiose. Arquivo Brasileiro de Medicina Veterinária e Zootecnia 57: 1-6.

PEREZ-DIAZ, I., HIRIART, M., OLIVARES-REYES, J.A., ROBLES-DIAZ, G. 2006. Receptores para la angiotensina II diferentes a los clásicos receptores membranales AT1 y AT2: Características y su papel en el funcionamiento celular. Revista de Educación Bioquímica 25: 55-60.

REGOLI, D., PARK, W.K., RIOUX, F. 1974. Pharmacology of angiotensin. Pharmacology & Therapeutics 26: 69-123.

RIPKEN, A., DEINERT, M. 2002. A clinical trial about efficacy of pimobendan in comparison to enalapril in dogs with mitral valve endocardiosis. Part 1: clinical, laboratory, radiologic and electrocardiographic results. DisponÌvel em www.vin.com/proceedings/proceedings.plx/cid=WSAVA.

ROTH, A.L. 1993. Use of angiotensin-converting-inhibitor in dog with congestive failure. Com Edu Rev 15: 1240-1244.

SABRI, A., RAFIQ, K., SEQQAT, R., KOLPAKOV, M.A., DILLON, R., DELL’ITALIA, L.J. 2008. Sympathetic activation causes focal adhesión signaling alteration in early compensated volumen overload attributable to isolated mitral regurgitation in the dog. Circulation Research 102: 1127-1136.

SEARLE, A. 1987. Vasodilatador: What they have to offer in management of congestive heart failure. Australian Veterinary Practitioner 17: 11-20.

SILVA, M.B., ALMEIDA, A.O., FADEL, L., AMBRÓSIO, C.E., MIGLINO, M.A. 2009. Influência do bloqueador de receptor de angiotensina (Losartana potássica) na função renal e pressão arterial em cães GRMD. Pesquisa Veterinária Brasileira 29: 322-326.

SILVA, M.B. 2009. O efeito do losartan na morfologia do músculo esquelético do modelo Golden Retriever Muscular Dystrophy: uma droga promissora para a regeneração da musculatura distrófica? Dissertação de mestrado. Faculdade de Medicina Veterinária e Zootecnia da universidade de São Paulo.

SISSON, D. 1991. Evidence for or against the efficacy of afterload reducers for management of Herat failure in dogs. Veterinary Clinics of North America: Small Animal Practice 21: 945-955.

SOARES, E.C., LARSSON, M.H.M.A., PINTO, A.C.B.C.F. 2004. Aspectos radiográficos na doença valvular crônica. Ciência Rural 34: 119-124.

SOARES, E.C., LARSSON, M.H.M.A., YANATO, R.J. 2005. Chronic valvular disease: correlation between clinical, eletrocardiographic, radiographic and echocardiographic aspects in dogs. Arquivo Brasileiro de Medicina Veterinária e Zootecnia 57: 436-441.

TILLEY, L.P. 1992. Interpretations of Q, R, S, T deflections. Págs. 59-99 en: Tilley, L.P. (Ed.). Essentials of canine and feline eletrocardiography. Tercera edición. Editorial Lea y Febiger. Phyladelphia.

VIGOA, A.V., ALVARES, N.C., DEL VALLE, Z.G., CRUZ, A.V. 1998. Antagonistas de los receptores de angiotensina II. Revista Cubana de Medicina 37: 83-92.

WOLF, R., CAMACHO, A.A., SOUZA, R.C.A. 2000. Eletrocardiografia computadorizada em cães. Arquivo Brasileiro de Medicina Veterinária e Zootecnia 52: 610-615.

Citado por

Artículos similares

También puede {advancedSearchLink} para este artículo.